https://www.selleckchem.com/products/ad-5584.html
Seroconversion rates for the four serogroups were 100%, 93.8%, 97.1%, and 94.1% after the first dose and 100%, 96.9%, 100%, and 100% after the second. Increases between doses were insignificant. There were no safety concerns. The two-dose series is well tolerated but clinical benefit of a second dose within 8 weeks seemed to be low.Our previous work have identified a novel oxazolidinones structure, biaryloxazolidinone analogues containing a hydrazone moiety, as promising antibacterial agents against Gram positive strains. Based on these
Like
Comment
Share
